Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC

Phase 2AK146D1IvonescimabPositive

AI Analysis

Summary

Akeso has dosed the first patient in a Phase II study of AK146D1, a TROP2/Nectin-4 bispecific ADC, in combination with Ivonescimab for advanced NSCLC. This represents the initiation of a clinical trial evaluating a novel bispecific antibody-drug conjugate.

Clinical Trial Data

Phase

Phase II

Outcome Details

First patient dosed in Phase II study

Importance:5/10

Sentiment:

0.40

bispecific ADCTROP2Nectin-4NSCLCcombination therapyclinical trial initiation

Related Companies

$9926.HK

Read the original article

Published by PR Newswire Biotech on July 20, 2026 5:32 AM

Read Original